Concepedia

Prediction model for hyperprogressive disease in non‐small cell lung cancer treated with immune checkpoint inhibitors

Yong Jun Choi, Taehee Kim, Eun Young Kim, Sang Hoon Lee, Do Sun Kwon, Yoon Soo Chang

Thoracic Cancer · 2020 · 31 citations · 29 references

DOIFull text

Open access

Abstract

This is the first study to develop a prediction model. The area under the curve of the prediction model for HPD was 0.9556.

References

29

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram et al. · CA A Cancer Journal for Clinicians · 2018 · 86.6K citations · Full text

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.3K citations · Full text

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer, Karen L. Reckamp, Paul Baas et al. · New England Journal of Medicine · 2015 · 8.4K citations · Full text

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst, Paul Baas, Dong‐Wan Kim et al. · The Lancet · 2015 · 6.4K citations

, , +7

Cancer statistics, 2000

Robert T. Greenlee, Thomas S. Murray, S. Bolden et al. · CA A Cancer Journal for Clinicians · 2000 · 3.9K citations · Full text

, , +14